Advertisement
UK markets close in 2 minutes
  • FTSE 100

    7,883.33
    +35.34 (+0.45%)
     
  • FTSE 250

    19,438.77
    +98.63 (+0.51%)
     
  • AIM

    745.42
    +2.30 (+0.31%)
     
  • GBP/EUR

    1.1688
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2467
    +0.0011 (+0.08%)
     
  • Bitcoin GBP

    51,097.84
    +2,153.52 (+4.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,052.82
    +30.61 (+0.61%)
     
  • DOW

    38,055.47
    +302.16 (+0.80%)
     
  • CRUDE OIL

    82.07
    -0.62 (-0.75%)
     
  • GOLD FUTURES

    2,397.60
    +9.20 (+0.39%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • DAX

    17,850.57
    +80.55 (+0.45%)
     
  • CAC 40

    8,034.00
    +52.49 (+0.66%)
     

How Geron Corporation (GERN) Stock Stands Out in a Strong Industry

One stock that might be an intriguing choice for investors right now is Geron Corporation GERN. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 29 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Geron Corporation is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Geron Corporation Price and Consensus

Geron Corporation Price and Consensus
Geron Corporation Price and Consensus

Geron Corporation price-consensus-chart | Geron Corporation Quote

ADVERTISEMENT

In fact, over the past month, current quarter estimates have narrowed from a loss of 10 cents per share to a loss of 6 cents per share, while current year estimates have narrowed from a loss of 48 cents per share to a loss of 28 cents per share. This has helped GERN to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.  You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Geron Corporation. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Geron Corporation (GERN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.